Simultaneous determination of iguratimod and its metabolite in rat plasma using a UPLC-MS/MS method: Application for drug-drug interaction

doi:10.1016/j.jpba.2024.116079

科研成果详情

题名	Simultaneous determination of iguratimod and its metabolite in rat plasma using a UPLC-MS/MS method: Application for drug-drug interaction
作者	Shi, Lu1; Hu, Jinyu1; Wu, Hualu1; Shen, Yuxin1; Chen, Xiaohai 1; Weng, Qinghua 2; Xu, Ren-ai1; Tang, Congrong1
发表日期	2024-06-15
发表期刊	Journal of pharmaceutical and biomedical analysis 影响因子和分区
语种	英语
原始文献类型	Journal Article
关键词	Fluconazole Iguratimod M2 Pharmacokinetics Rat UPLC-MS/MS
摘要	This aim of the work was to establish an acceptable sensitive assay based on ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) for quantitatively analyzing the plasma concentrations of iguratimod (IGR) and its metabolite M2 in rats, and to further investigate the effect of fluconazole on the pharmacokinetics of IGR and M2. The mobile phase consisted of acetonitrile and water with 0.1% formic acid, was used to separate IGR, M2 and internal standard (IS) fedratinib on a UPLC BEH C18 column (2.1 mm × 50 mm, 1.7 μm) with the flow rate of 0.4 mL/min. Positive ion mode and multiple reaction monitoring (MRM) were used to construct the quantitative analysis. The calibration standard of IGR and M2 covered 2-10000 and 1-1000 ng/mL respectively, with the lower limit of quantification (LLOQ) as 2 ng/mL and 1 ng/mL respectively. In addition, selectivity, recovery, accuracy, precision, matrix effect and stability of the method validation program were well accepted in this work. Subsequently, this approach was used to assess the effect of fluconazole on the pharmacokinetics of IGR and M2 in rats. In the presence of 20 mg/kg fluconazole (experimental group), we found the main pharmacokinetic parameters were significantly altered when compared with 2.5 mg/kg IGR alone (control group). Among them, AUC(0-∞) and Cmax of IGR in the experimental group was 1.43 and 1.08 times higher than that of the control group, respectively. Moreover, we also found that the other main pharmacokinetic parameters of M2 had no significant changes, except t1/2z and Tmax. In conclusion, fluconazole significantly altered the main pharmacokinetics of IGR and M2 in rats. It implys that we should pay more attention to the adverse reaction of IGR when the concomitant use of fluconazole and IGR occur in the future clinical practice
出版者	ELSEVIER
ISSN	0731-7085
EISSN	1873-264X
卷号	243
DOI	10.1016/j.jpba.2024.116079
页数	6
WOS类目	Chemistry, Analytical ; Pharmacology & Pharmacy
WOS研究方向	Chemistry ; Pharmacology & Pharmacy
WOS记录号	WOS:001206348900001
收录类别	PUBMED ; SCOPUS ; SCIE
URL	查看原文
PubMed ID	38471255
SCOPUSEID	2-s2.0-85187497034
通讯作者地址	[Xu, Ren-ai]The First Affiliated Hospital of Wenzhou Medical University,Zhejiang,Wenzhou,China
Scopus学科分类	Analytical Chemistry;Pharmaceutical Science;Drug Discovery;Spectroscopy;Clinical Biochemistry
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/210259
专题	附属第一医院其他_附属第三医院（瑞安市人民医院）
通讯作者	Xu, Ren-ai
作者单位	1.The First Affiliated Hospital of Wenzhou Medical University,Zhejiang,Wenzhou,China; 2.The Third Affiliated Hospital of Shanghai University (Wenzhou People's Hospital),The Third Clinical Institute Affiliated to Wenzhou Medical University,Zhejiang,China
第一作者单位	附属第一医院; 第一临床医学院（信息与工程学院）、附属第一医院
通讯作者单位	附属第一医院; 第一临床医学院（信息与工程学院）、附属第一医院
第一作者的第一单位	附属第一医院
推荐引用方式 GB/T 7714	Shi, Lu,Hu, Jinyu,Wu, Hualu,et al. Simultaneous determination of iguratimod and its metabolite in rat plasma using a UPLC-MS/MS method: Application for drug-drug interaction[J]. Journal of pharmaceutical and biomedical analysis,2024,243.
APA	Shi, Lu., Hu, Jinyu., Wu, Hualu., Shen, Yuxin., Chen, Xiaohai., ... & Tang, Congrong. (2024). Simultaneous determination of iguratimod and its metabolite in rat plasma using a UPLC-MS/MS method: Application for drug-drug interaction. Journal of pharmaceutical and biomedical analysis, 243.
MLA	Shi, Lu,et al."Simultaneous determination of iguratimod and its metabolite in rat plasma using a UPLC-MS/MS method: Application for drug-drug interaction".Journal of pharmaceutical and biomedical analysis 243(2024).